Role of myokines and osteokines in cancer cachexia
Authors:
- 25 April 2021
- journal article
- research article
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 246 (19) , 2118-2127
Abstract
Cancer-induced muscle wasting, i.e. cachexia, is associated with different types of cancer such as pancreatic, colorectal, lung, liver, gastric and esophageal. Cachexia affects prognosis and survival in cancer, and it is estimated that it will be the ultimate cause of death for up to 30% of cancer patients. Musculoskeletal alterations are known hallmarks of cancer cachexia, with skeletal muscle atrophy and weakness as the most studied. Recent evidence has shed light on the presence of bone loss in cachectic patients, even in the absence of bone-metastatic disease. In particular, we and others have shown that muscle and bone communicate by exchanging paracrine and endocrine factors, known as myokines and osteokines. This review will focus on describing the role of the most studied myokines, such as myostatin, irisin, the muscle metabolite β-aminoisobutyric acid, BAIBA, and IL-6, and osteokines, including TGF-β, osteocalcin, sclerostin, RANKL, PTHrP, FGF23, and the lipid mediator, PGE2during cancer-induced cachexia. The interplay of muscle and bone factors, together with tumor-derived soluble factors, characterizes a complex clinical scenario in which musculoskeletal alterations are amongst the most debilitating features. Understanding and targeting the “secretome” of cachectic patients will likely represent a promising strategy to preserve bone and muscle during cancer cachexia thereby enhancing recovery.Keywords
Funding Information
- V Foundation for Cancer Research (V2017-021)
- National Institute on Aging (PO1 AGO39355)
- American Cancer Society (132013-RSG-18-010-01-CCG)
This publication has 97 references indexed in Scilit:
- The Multifaceted Actions of PTHrP in Skeletal MetastasisFuture Oncology, 2012
- IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the Apc Min/+ mouseSkeletal Muscle, 2012
- A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesisNature, 2012
- STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer CachexiaPLOS ONE, 2011
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanismJournal of Bone and Mineral Research, 2011
- Interleukin 6 as a Key Regulator of Muscle Mass during CachexiaExercise and Sport Sciences Reviews, 2010
- Skeletal muscle weakness in osteogeneis imperfecta miceMatrix Biology, 2010
- Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube sizeAmerican Journal of Physiology-Cell Physiology, 2009
- Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloadingBone, 2007